Table 3.
The Response of DR1-Tg+ T Cells to hCII Is Restricted by HLA-DR1
| T cell hybridoma | APC* | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Chimeric DR1 | DR1 | I-Af | ||||||||
| + Antigen‡ | − Antigen | + Antigen | − Antigen | + Antigen | ||||||
| DR1hCII-2.0 | >2,560 | –§ | >2,560 | – | – | |||||
| DR1hCII-3.0 | >2,560 | – | >2,560 | – | – | |||||
| DR1hCII-14.0 | >2,560 | – | >2,560 | – | – | |||||
| DR1hCII-16.0 | 2,560 | – | >2,560 | – | – | |||||
| DR1hCII-19.0 | 2,560 | – | >2,560 | – | – | |||||
| DR1hCII-22.0 | >2,560 | – | >2,560 | – | – | |||||
*
APCs: DRAB10, transfected cells that express the chimeric DR1; L57, transfected L cells expressing wild-type DR1; and, the B cell hybridoma 43.2.1 that expresses I-Af.
‡
Antigen presentation assay performed as described in Materials and Methods. hCII(249–281) was used as antigen at 150 μg/ml final concentration.
§
−, less than 20 U/ml of IL-2 produced.